Latest news

European doctors learn to access the heart from any approach with Baylis devices and expanded training program

European doctors learn to access the heart from any approach with Baylis devices and expanded training program

Date:

FOR IMMEDIATE RELEASE

European doctors learn to access the heart from any approach with Baylis devices and expanded training program


 
TORONTO, November 21, 2017— Baylis Medical Company Inc. has launched a hands-on workshop in Europe that will train cardiologists on innovative tools that enable access to the heart from any approach. This includes a growing number of procedures that require physicians to use major veins that feed into the heart from above – something the Baylis Medical SupraCross® RF System enables with ease.


Such alternate pathways offer a minimally invasive way to deliver life-saving treatments. Prior to the development of these tools, open heart surgery was the only option available for many high-risk patients.


Following its initial launch in Toronto, Canada, the SupraCross® Workshop has now expanded to Europe, a growing market for this one-of-a-kind technology. The program offers specialized training on the use of the Baylis Medical SupraCross RF System to interventional cardiologists – specialized physicians who provide catheter-based treatment of various heart diseases. 
“The SupraCross workshop was excellent,” says Dr. Zachary Whinnett, a consultant cardiologist and electrophysiologist at Hammersmith Hospital, London UK, who participated in a recent Baylis training workshop in Amsterdam. “The superb hands-on experience with these advanced tools made superior access to the left atrium easy.”


Baylis Medical’s SupraCross RF System includes a steerable sheath and flexible radiofrequency wire that were designed to achieve controlled and precise transseptal access to the left side of the heart from any approach, including from above the heart.  For example, these dedicated tools make it easier for physicians to place a pacemaker lead into the left heart in cases where traditional cardiac resynchronization therapy fails. 


“These tools are also used for accessing the heart from the subclavian vein or internal jugular vein above the heart in cases where the lower femoral vein is blocked or does not otherwise have a continuous pathway to the heart,” says Chris Bermingham, Team Leader, Clinical Education at Baylis. “This is a technically challenging procedure for even the most skilled physician, unless you have the right tools.”


“Baylis is committed to developing innovative solutions that help all patients, particularly those for whom no other medical options are available,” says Kris Shah, President of Baylis Medical. “That’s why we developed the SupraCross system, and why we are expanding our specialized training program to Europe. We know the importance of offering best-in-class clinical support to physicians who must stay abreast of a constantly evolving medical field.”


About Baylis Medical Company
Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology, interventional radiology, and spinal procedures. Our vision is to develop and market innovative medical therapies while improving the lives of people around the world. The company has offices in Montreal and Toronto (Canada), Boston (U.S.), London (U.K.) and Munich (Germany).  For more information, visit www.baylismedical.com. 


Media Contacts:
Laura Mills
Marketing Manager
Baylis Medical Company
Tel: 905.602.4875 ext. 292
lmills@baylismedical.com
www.baylismedical.com


PRM-00273 EN J-1,2,3 V-1 © Copyright Baylis Medical Company Inc., 2017. Baylis Medical Company Inc. reserves the right to change specifications or to incorporate design changes without notice and without incurring any obligation relating to equipment previously manufactured or delivered. SupraCross and the Baylis Medical logo are trademarks and/or registered trademarks of Baylis Medical Company Inc.in the USA and/or other countries. Patents Pending and/or issued. CAUTION: Federal Law (USA) restricts the use of these devices to or by the order of a physician. Before use, consult product labels and Instructions for Use for Indications for Use, Contraindications, Warnings, Precautions, Adverse Events and Directions for Use.

Baylis Medical’s Kris Shah appointed to AdvaMed Accel Board of Directors

Baylis Medical’s Kris Shah appointed to AdvaMed Accel Board of Directors

Date:

FOR IMMEDIATE RELEASE

Baylis Medical’s Kris Shah appointed to AdvaMed Accel Board of Directors

 
Washington, DC, October 25, 2017— Baylis Medical Company, a leading developer, manufacturer, and supplier of state-of-the-art interventional cardiology products, has announced that President and co-Founder Kris Shah has been named to the Advanced Medical Technology Association's (AdvaMed) Accel Board of Directors.


“I am honoured to be appointed to the AdvaMed Accel Board and look forward to working with this distinguished group of professionals to advance medical innovations that result in healthier lives and healthier economics around the world,” said Mr. Shah. “I am particularly pleased to be joining an association that shares Baylis Medical’s adherence to the highest ethical standards and commitment for improving patients’ lives.”


“We are pleased to have Kris joining our Accel Board of Directors,” said Ashley Wittorf, Executive Director, AdvaMed Accel. “His business, engineering and commercialization experience bring a wealth of expertise to the Accel Board. In addition, his insight into international markets will be invaluable as we address the unique overseas challenges facing smaller medtech companies."


About Baylis Medical Company
Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology, interventional radiology, and spinal procedures. Our vision is to develop and market innovative medical therapies while improving the lives of people around the world. The company has offices in Montreal and Toronto (Canada), Boston (U.S.), London (U.K.) and Munich (Germany).  For more information, visit www.baylismedical.com. 


About AdvaMed Accel
AdvaMed Accel is the division within AdvaMed dedicated to addressing the unique needs and challenges of smaller medical device and diagnostics manufacturers – the lifeblood of the medical technology industry. The only organization of its kind focusing specifically on the needs of the medtech industry’s emerging growth companies, AdvaMed Accel works to create a policy environment more conducive to capital formation and innovation. For more information, visit www.advamedaccel.org.


Media Contact:

Laura Mills
Marketing Manager
Baylis Medical Company
Tel: 905.602.4875 ext. 292
lmills@baylismedical.com
www.baylismedical.com


PRM—00266 EN J-1,2,3 V-1 © Baylis Medical Company Inc., 2017.
Baylis Medical and Siemens Healthineers co-sponsor physician training for state-of-the art, minimally invasive heart procedure

Baylis Medical and Siemens Healthineers co-sponsor physician training for state-of-the art, minimally invasive heart procedure

Date:

FOR IMMEDIATE RELEASE

Baylis Medical and Siemens Healthineers co-sponsor physician training for state-of-the art, minimally invasive heart procedure


TORONTO, October 17, 2017—Baylis Medical Company Inc. and Siemens Healthineers are co-sponsoring a first-of-its kind training program aimed at helping cardiologists perform a complex procedure that is quickly becoming the gold standard for treating patients with atrial fibrillation and other structural heart diseases.


The two companies are working with a network of highly respected physicians to offer the Baylis Education Hands-On Transseptal Course. This hands-on training program was launched in response to the growing need for minimally invasive procedures that require access to the left side of the heart. For example, a transseptal puncture through the septum is a standard procedure for accessing the left atrium. 


“There has been a huge growth in left-side structural procedures which all require very precise transseptal access, yet many interventional cardiologists and cardiac surgeons haven’t had the opportunity to learn transseptal techniques,” says instructor Dr. Brijeshwar Maini, interventional cardiologist and regional medical director of transcatheter therapies for Tenet Healthcare's Florida Region. “Our first course got very positive feedback from physicians. They recognize the importance in gaining experience with the best available tools to ensure the best possible outcomes for their patients.” 


Interventional cardiologists – specialized physicians who provide catheter-based treatment of various heart diseases – have previously used a sharp mechanical needle to access the left side of the heart, which has been demonstrated in comparative clinical studies to be more time-consuming and have a higher risk of complications, such as cardiac tamponade, relative to using a radiofrequency needle. Procedural complications may result in longer hospital stays and higher per-patient costs. Published studies have found that the Baylis Radiofrequency NRG® Transseptal Needle Transseptal RF solution, which uses a short and highly focused RF energy pulse, allows a puncture that is more predictable and has the potential to minimize complications.


The combination of growing medical need coupled with the availability of smaller and more sophisticated cardiac implants is making catheter-based procedures more common. The new educational course offered by Baylis and Siemens Healthineers provides interventional cardiologists and surgeons with the skills they need to use more high-tech tools that provide greater precision and less risk in accessing the left atrium. The tools in this course include Baylis’ NRG® Transseptal Needle and Siemens Healthineers ACUSON SC2000™ PRIME ultrasound system. 


“Patients suffering with atrial fibrillation or structural heart disease traditionally had to undergo high-risk open-heart surgeries,” says Kris Shah, President of Baylis Medical. “Today, state-of-the-art technologies like the Baylis RF Transseptal solution enable targeted and precise access to the left atrium. Such minimally invasive procedures typically result in lower risk to the patient, less trauma and a faster recovery.”


Interventional cardiologists and cardiac surgeons are also increasingly relying on visualization tools to accurately guide catheters and implants within the beating heart. 


“We are pleased to join with Baylis Medical in co-sponsoring training in such a rapidly growing medical segment where precise guidance is key,” says Peter Pellerito, Senior Vice President, Ultrasound North America, Siemens Healthineers. “Siemens Healthineers ACUSON SC2000 PRIME TEE and ICE tools offer ultrasound images that help make complex transseptal structural heart procedures straightforward. Physicians attending the course are able to use tools such as real-time septal guidance for more precise septal crossing and better outcomes. As more physicians gain experience in interpreting these images, we could see these innovative procedures replacing the majority of open-heart surgeries in the years ahead.”


Baylis and Siemens Healthineers sponsored the first joint course this past spring in Atlanta, GA. Based on positive feedback from participants, the companies partnered to offer the course in other U.S. cities. 


About Baylis Medical Company
Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology, interventional radiology, and spinal procedures. Our vision is to develop and market innovative medical therapies while improving the lives of people around the world. The company has offices in Montreal and Toronto (Canada), Boston (U.S.), London (U.K.) and Munich (Germany).  For more information, visit www.baylismedical.com. 


About Siemens Healthineers
Siemens Healthineers is the separately managed healthcare business of Siemens AG enabling healthcare providers worldwide to meet their current challenges and to excel in their respective environments. A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Siemens Healthineers is also actively developing its digital health services and enterprise services. To help customers succeed in today's dynamic healthcare marketplace, Siemens Healthineers is championing new business models that maximize opportunity and minimize risk for healthcare providers. In fiscal 2016, which ended on September 30, 2016, Siemens Healthineers generated revenue of €13.5 billion and profit of over €2.3 billion and has about 46,000 employees worldwide. Further information is available on the Internet at www.siemens.com/healthineers.


Media Contacts:

Laura Mills
Marketing Manager
Baylis Medical Company
Tel: 905.602.4875 ext. 292
lmills@baylismedical.com
www.baylismedical.com

Jeff Bell
Senior Manager, Media Relations
Siemens Healthineers
Tel: (484) 868-8346
jeffrey.t.bell@siemens-healthineers.com 
www.siemens.com/healthineers

PRM—00255 EN J-1,2,3 V-1 © Baylis Medical Company Inc., 2017. CAUTION: Federal Law (USA) restricts the use of these devices to or by the order of a physician. Before use, consult product labels and Instructions for Use for Indications for Use, Contraindications, Warnings, Precautions, Adverse Events and Directions for Use.  The Baylis Medical logo and NRG are trademarks or registered trademarks of Baylis Medical Company Inc. in the USA and/or other countries.  Other trademarks are property of their respective owners.

References:
 Hsu JC, Badhwar N, Gerstenfeld EP, Lee RJ, Mandyam MC, Dewland TA, Imburgia KE, Hoffmayer KS, Vedantham V, Lee BK, Tseng ZH, Scheinman MM, Olgin JE, Marcus GM. Randomized trial of conventional transseptal needle versus radiofrequency energy needle puncture for left atrial access (the TRAVERSE-LA study). J Am Heart Assoc. 2013 Sep 17;2(5): e000428.
Winkle RA, Mead RH, Engel G, Patrawala RA. The use of a radiofrequency needle improves the safety and efficacy of transseptal puncture for atrial fibrillation ablation. Heart Rhythm. 2011 Sep;8(9):1411-5.

IIbid

Baylis Medical teams with national Centre of Excellence to improve the lives of people with atrial fibrillation

Baylis Medical teams with national Centre of Excellence to improve the lives of people with atrial fibrillation

Date:

Baylis Medical teams with national Centre of Excellence to improve the lives of people with atrial fibrillation

More physicians will soon be evaluating an innovative radio frequency (RF) needle developed by Baylis Medical Company Inc. as part of a cross-Canada clinical trial in people with atrial fibrillation (AF). It is the most common heart arrhythmia abnormality and accounts for the majority of arrhythmia-related emergency room visits and hospital admissions.
Previous studies have demonstrated that the RF needle can be faster, safer and more effective than a mechanical needle for unrelated procedures.  Positive results from the CANet study would complement and expand this growing body of evidence.

The 150-patient, multi-centre randomized controlled trial is being sponsored by the Cardiac Arrhythmia Network of Canada (CANet), a national research network that brings together health care professionals, academia, government, industry, not-for-profit organizations, and patients to evaluate and put into practice innovative technologies that improve patient care. The study is one of several CANet-supported projects aimed at reducing AF-related emergency department visits and hospitalization, and the latest in a series of such projects in which Baylis has collaborated.

“Baylis is excited to be partnering once again with CANet, which shares our passion for improving patient care and working with hospitals to facilitate the adoption of safe and effective technologies,” says Kris Shah, President of Baylis Medical, which is providing local physicians with its commercial product and training on how to use it. “Access to CANet’s leading-edge network of investigators allows us to introduce our therapies to even more hospitals, and bring relief to patients, faster.”

Dr. Jason Andrade, the study’s principle investigator, says “Given the number of patients suffering with atrial fibrillation, and the significant healthcare costs associated with managing it, there is a critical need for innovative minimally invasive cardiac procedures that improve patient outcomes without increasing healthcare costs”. 

“In August, Dr. Peter Leong-Sit at London Health Sciences became the first physician in this trial to use the Baylis left atrial access equipment, which included the Baylis RF needle, and the surgery was a success,” says Dr. Andrade, Director of Electrophysiology at Vancouver General Hospital. 

The clinical study is evaluating two different technologies for accessing the left atrium, which is required for AF ablation procedures as well as the treatment of certain structural heart diseases. One technology is Baylis’ NRG® Transseptal Needle, a blunt-tipped electrode that delivers a short and a highly focused RF energy pulse, allowing a puncture that is more predictable and has the potential to minimize complications. Researchers will also evaluate a procedure where heart rhythm specialists push a sharp, mechanical needle to puncture the tissue. This traditional technique has been demonstrated in comparative clinical studies to be more time-consuming and to lead to complications, such as cardiac tamponade. Procedural complications may result in longer hospital stays and higher per-patient costs.

This will be the first study evaluating the use of Baylis’ Transseptal equipment during a special type of atrial fibrillation procedure that uses a cryoablation balloon catheter to ablate tiny areas in the heart that cause rapid and irregular heartbeats.

Dr. Allan Skanes, CANet’s AF Theme Leader and Director of the London Heart Rhythm Program, has described the Baylis technology as a “slicker and more useful version of the old sharp needle technique” that gives physicians greater control and precision in crossing the septum. Baylis’ product is designed and manufactured in Canada, and cleared for use in several jurisdictions, including Canada, the U.S., EU and Japan.

CANet’s Scientific Director and CEO Dr. Anthony Tang says the study serves as an example of how clinicians and industry partners can work together to improve patient outcomes and enhance productivity in the healthcare system.

“We hope from this study to demonstrate that by treating patients earlier in their disease, we can potentially reduce the risk of stroke and other heart problems from occurring later. The goal is to see this surgical intervention become a frontline treatment for more patients in Canada, and around the world.” says Dr. Tang.

The early release of Baylis’ NRG® Transseptal Needle was made possible, in part, by a repayable matching contribution of $15.2 million from the Federal Economic Development Agency for Southern Ontario (FedDev Ontario) through its Advanced Manufacturing Fund. 

“We are pleased to match Baylis’ investment to accelerate the development and commercialization of the first-in-Canada medical devices that will be used by doctors during heart procedures,” says the Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development and Minister responsible for FedDev Ontario. “Such innovative and transformative products are expanding international markets for made-in-Canada technologies that have a positive impact on patients around the world.”

About Baylis Medical Company
Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology, interventional radiology, and spinal procedures. Our vision is to develop and market innovative medical therapies while improving the lives of people around the world. The company has offices in Montreal and Toronto (Canada), Boston (U.S.), London (U.K.) and Munich (Germany).  For more information, visit www.baylismedical.com. 

Media Contact:
Laura Mills
Marketing Manager
Baylis Medical Company
Tel: 905.602.4875 ext. 292
lmills@baylismedical.com
www.baylismedical.com

About CANet:
The Cardiac Arrhythmia Network of Canada (CANet) is a not-for-profit organization dedicated to transforming Canada’s arrhythmia health care system through integrated trans-disciplinary research and development. The network’s strategy is to invent, prove, and implement innovative solutions to enable patients to take ownership and co-manage their arrhythmia health. CANet is funded by the federal government’s Networks of Centres of Excellence (NCE), Canada’s flagship science and technology program.

References:
IJason G Andrade, MD, Marc Dubuc, MD, Peter G Guerra, MD, Laurent Macle, MD, Lena Rivard, MD, Denis Roy, MD, Mario Talajic, MD, Bernard Thibault, MD, and Paul Khairy, MD, PhD. Cryoballoon Ablation for Atrial Fibrillation, Indian Pacing Electrophysiology Journal. 2012. Mar-Apr; 12(2): 39–53.

IIWinkle RA, Mead RH, Engel G, Patrawala RA. The use of a radiofrequency needle improves the safety and efficacy of transseptal puncture for atrial fibrillation ablation. Heart Rhythm. 2011 Sep;8(9):1411-5.

Hsu JC, Badhwar N, Gerstenfeld EP, Lee RJ, Mandyam MC, Dewland TA, Imburgia KE, Hoffmayer KS, Vedantham V, Lee BK, Tseng ZH, Scheinman MM, Olgin JE, Marcus GM. Randomized trial of conventional transseptal needle versus radiofrequency energy needle puncture for left atrial access (the TRAVERSE-LA study). J Am Heart Assoc. 2013 Sep 17;2(5): e000428.

IIIIbid

IVIbid

PRM-00245 EN J-1,2,3 V-2 © Baylis Medical Company Inc., 2017. Baylis Medical Company Inc. reserves the right to change specifications or to incorporate design changes without notice and without incurring any obligation relating to equipment previously manufactured or delivered. NRG and the Baylis Medical logo are trademarks and/or registered trademarks of Baylis Medical Company Inc. in the USA and/or other countries. CAUTION: Federal Law (USA) restricts the use of these devices to or by the order of a physician. Before use, consult product labels and Instructions for Use for Indications for Use, Contraindications, Warnings, Precautions, Adverse Events and Directions for Use. Patents pending and/or issued.
Baylis Medical strengthens global expansion plans with senior hire

Baylis Medical strengthens global expansion plans with senior hire

Date:

For Immediate Release

BAYLIS MEDICAL STRENGTHENS GLOBAL EXPANSION PLANS WITH SENIOR HIRE


TORONTO, August 23, 2017—Baylis Medical Company Inc. has recruited a seasoned industry executive to lead a growing global sales team to fast-track the company’s expansion into existing and new international markets. Baylis, a leading developer, manufacturer, and supplier of state-of-the-art interventional cardiology products, is pleased to announce that Thomas Chavez has joined the company in the new position of Global Vice President of Sales, Cardiology.

“Thomas’ appointment will be a key driver in accelerating our global commercialization strategy,” says Kris Shah, President of Baylis Medical. “His extensive international sales experience combined with his strategic insight into the medical device market will deepen our relationships with existing customers in Canada, Japan, Europe and United States, while opening new opportunities in China, elsewhere in Asia and the Middle East. With this appointment, Baylis is on track to fulfil its mission to be a world leader in the development and distribution of innovative, high-technology products that will improve the lives of people around the world.”
 
Chavez’s responsibilities include executing a dynamic global marketing strategy, managing key distributor relationships, and mentoring and growing a team of sales professionals beyond existing markets in the U.S., Canada and Europe. He will focus on expanding the market for Baylis’ existing line of medical products, as well as opening new markets for products currently in the development pipeline. Baylis has sales offices in Toronto and Montreal (Canada), Boston (U.S.), London (U.K.) and Munich (Germany). 

“I’m excited to join a company with such a passion for patient care,” says Chavez, who will work from both Austin, Texas and Toronto. “That commitment nurtures a culture within our organization that is nimble, innovative and socially responsible. Baylis’ focus on solving disease state issues means the technologies produced are both clinically relevant and economically sound which provides value to the patient and customer alike.”

Chavez has 30 years of medical device experience with over half of that time at the executive level running large-scale sales, marketing and corporate account organizations. For over 15 years he worked at St. Jude Medical, a global medical device company headquartered near Saint Paul, Minnesota, where he held a variety of executive positions, including Senior Vice President. Most recently, he was Vice President for the Americas at Smith Medical and prior to that he was with Zimmer Orthopedics. His experience extends across broad categories and disease states, including electrophysiology, cardiac rhythm management, cardiac valves, orthopedics and drug delivery.  

“Many of the organizations I have worked with compete in similar or adjacent markets, and developed innovative and successful solutions to a changing healthcare system. I look forward to applying that experience to ensure that even more people will benefit from Baylis Medical’s innovations,” says Chavez.

“Thomas is a perfect fit for our company. He has deep sales and marketing experience in the field of cardiology, particularly cardiac electrophysiology and structural heart products,” adds Shah. “He is also a good fit with the Baylis culture. He will play a strategic role in helping our company learn new skills, grow our team and expand our business globally.”

About Baylis Medical Company
Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology, interventional radiology, and spinal procedures. Our vision is to develop and market innovative medical therapies while improving the lives of people around the world. The company has offices in Montreal and Toronto (Canada), Boston (U.S.), London (U.K.) and Munich (Germany).  For more information, visit www.baylismedical.com. 

Media Contact:
Laura Mills
Marketing Manager
Baylis Medical Company
Tel: 905.602.4875 ext. 292
lmills@baylismedical.com
www.baylismedical.com

PRM-00234 EN J-1,2,3 V-1© Baylis Medical Company Inc., 2017. The Baylis Medical logo is a registered trademark of Baylis Medical Company Inc. in the USA and/or other countries. CAUTION: Federal Law (USA) restricts the use of these devices to or by the order of a physician. Before use, consult product labels and Instructions for Use for Indications for Use, Contraindications, Warnings, Precautions, Adverse Events and Directions for Use.

St. Michael’s cardiologist performs successful world first, using a novel Canadian-invented device

Date:

For Immediate Release

ST. MICHAEL’S CARDIOLOGIST PERFORMS SUCCESSFUL WORLD FIRST, USING A NOVEL CANADIAN-INVENTED DEVICE


TORONTO, May 24, 2017—When Dr. Neil Fam examined his 86-year-old patient with severe mitral regurgitation—a condition in which the blood flows backward into the heart after it contracts—his options for treating her were limited.

Because of her age and overall health, Ortensia Aceti of Sault Ste. Marie, Ont., was not a good candidate for surgery to repair her mitral valve, the flap between the two left chambers of her heart. She had been in and out of hospital with heart failure, and medication was no longer controlling her symptoms.

Instead, Dr. Fam decided on a catheter-based treatment to guide a MitraClip® device to the heart and clamp the leaky valve. The catheter would usually be inserted through the femoral vein in the leg, but her vein was blocked.

“We were locked out, blocked from accessing her heart,” said Dr. Fam, an interventional cardiologist and director of the Cardiac Intensive Care Unit of St. Michael’s Hospital in Toronto.

Dr. Fam recalled a conversation he had about a year previously with Baylis Medical Company, Inc., a Canadian supplier of high-tech cardiology equipment, about their SupraCross® RF Solution, which includes a steerable sheath and radiofrequency wire that were designed to achieve transseptal access to the heart from alternative approaches. These devices can enter the body through the jugular vein in the neck, enabling access to the leaky valve despite the blockage in her leg.

For the first time in the world, Dr. Fam successfully used the SupraCross® RF Solution to guide a MitraClip® device through the jugular vein into the heart and successfully repair a leaking mitral valve.

Dr. Fam said this was possible, despite the awkward angle of the jugular vein in relation to the heart, because the tip of the sheath is steerable and the wire is equipped to deliver radiofrequency energy to puncture the septum of the heart. This allows the physician to position the system appropriately from this challenging angle, and puncture the septum in a precise and controlled manner without using excessive force. The septum is the dividing wall between the left and right sides of the heart and it’s the last barrier to getting to the mitral valve, which sits between the left ventricle and the left atrium.

Dr. Fam said that Mrs. Aceti had no complications and that her condition improved, allowing her to be discharged to her home. At a follow-up appointment, the patient was doing well with no further heart failure.

Sue Carlucci, one of Mrs. Aceti’s three daughters, said that Dr. Fam explained the novel procedure to the family carefully in advance.

“If Dr. Fam hadn’t suggested this procedure, we probably would have lost our mom,” she said.

“He’s our angel,” she said, referring to St. Michael’s nickname, the Urban Angel.

Dr. Fam said that while this procedure would be appropriate for only selected patients, they are high-risk patients for which there may be no other treatment options.

“Given the success of this procedure, the door is open for future studies of the jugular approach for treating the mitral valve,” he said.

Dr. Fam published a report of this procedure in the journal Eurointervention on May 9.

About St. Michael’s Hospital 
St. Michael’s Hospital provides compassionate care to all who enter its doors. The hospital also provides outstanding medical education to future health care professionals in more than 29 academic disciplines. Critical care and trauma, heart disease, neurosurgery, diabetes, cancer care, care of the homeless and global health are among the hospital’s recognized areas of expertise. Through the Keenan Research Centre and the Li Ka Shing International Healthcare Education Center, which make up the Li Ka Shing Knowledge Institute, research and education at St. Michael’s Hospital are recognized and make an impact around the world. Founded in 1892, the hospital is fully affiliated with the University of Toronto.

For more information, or to interview Dr. Fam please contact:
Leslie Shepherd
Manager, Media Strategy
Phone: 1-416-864-6094
shepherdl@smh.ca
St. Michael’s Hospital
Inspired Care. Inspiring Science.
 
About Baylis Medical Company
Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology, interventional radiology, and spinal procedures.  Our vision is to develop and market innovative medical therapies while Improving the Lives of People Around the World.  The company has offices in Montreal and Toronto (Canada), Boston (USA), London (U.K.) and Munich (Germany).  For more information, visit www.baylismedical.com. 
 
Media Contact Person:
Laura Mills
Marketing Manager
Baylis Medical Company
Tel: 905.602.4875 ext. 292
lmills@baylismedical.com
www.baylismedical.com
 
© Baylis Medical Company Inc., 2017. The Baylis Medical logo and SupraCross are trademarks and/or registered trademarks of Baylis Medical Company Inc. in the USA and/or other countries. All other trademarks are the property of their respective owners. CAUTION: Federal Law (USA) restricts the use of these devices to or by the order of a physician. Before use, consult product labels and Instructions for Use for Indications for Use, Contraindications, Warnings, Precautions, Adverse Events and Directions for Use.
Baylis Medical Broadens Medtronic Partnership With Expanded Indications For The Osteocool™ RF Ablation System

Baylis Medical Broadens Medtronic Partnership With Expanded Indications For The Osteocool™ RF Ablation System

Date:

Baylis Medical Broadens Medtronic Partnership With Expanded Indications For The Osteocool™ RF Ablation System



(Montreal, Canada, February 15, 2017)

Baylis Medical Company announces U.S. Food and Drug Administration (FDA) 510(k) indication expansion of the OsteoCool™ RF Ablation System to include coagulation and ablation of tissue in bone during surgical procedures including palliation of pain associated with metastatic lesions involving bone in patients who have failed or are not candidates for standard therapy. The OsteoCool™ System was previously indicated for use in the spine, which remains part of its intended use.  With the expanded indication, the technology may now be used for palliative treatment of metastases in all bony anatomy - such as ribs, sacrum, extremities, and hip. 


The indication expansion was cleared just one year after Medtronic acquired the OsteoCool™ technology and associated intellectual property from Baylis Medical.  Subsequently, Baylis Medical broadened the partnership in leading the pursuit of the FDA 510(k) indication expansion.

  

Metastatic bone disease has been reported to occur in 60-80% of cancer patients, most frequently among patients with primary malignancies of the breast, prostate, liver, and lung.i  More than 80% of bone metastases are found in the axial skeleton, which includes the skull, spine, and ribs.ii


The OsteoCool™ System enables minimally-invasive treatment of patients suffering from painful malignant metastases in peripheral bone, the first treatment of its kind in the U.S. The OsteoCool™ System is the only cooled radiofrequency (RF) ablation technology designed to perform optimally in bone that offers simultaneous, dual-probe capabilities – providing for procedural flexibility and predictable, customized treatment. Cooled RF ablation uses targeted radiofrequency energy to ablate metastatic malignant lesions.

 

"We're pleased to broaden our partnership with Medtronic to improve the treatment of patients suffering from painful metastases," said Kris Shah, president of Baylis Medical.  "The expansion of the OsteoCool™ System to include the ablation of malignant lesions in bone adds to our company’s track record of offering innovative clinical solutions and further enhancing patient access and treatment options.”


"Our Pain Therapies business is deeply rooted in the Medtronic Mission – which calls us to alleviate pain,” said Jeff Cambra, General Manager of the Pain Therapies Interventional business, which is part of the Restorative Therapies Group at Medtronic. “With this expanded indication, we put an important treatment option into the hands of physicians so that they can help more patients suffering from debilitating pain.”


About Baylis Medical Company

Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology, interventional radiology, and spinal procedures.  Our vision is to develop and market innovative medical therapies while Improving the Lives of People Around the World.  The company has offices in Montreal and Toronto (Canada), Boston (USA), London (U.K.) and Munich (Germany).  For more information, visit www.baylismedical.com. 

Media Contact Person:

Laura Mills

Marketing Manager

Baylis Medical Company

Tel: 905.602.4875 ext. 292

lmills@baylismedical.com

www.baylismedical.com


About Medtronic

Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 85,000 people worldwide, serving physicians, hospitals and patients in approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.


i Schuleman et al. Economic Burden of Metastatic Bone Disease. American Cancer Society, 2007.

ii Nielson et al. Bone Metastases: Pathophysiology and Management Policy. American Society of Clinical Oncology, 1991.


PRM-00156 EN J-1,2,3 V-1 © Baylis Medical Company Inc., 2017. The Baylis Medical logo is a trademark and/or registered trademark of Baylis Medical Company Inc. in the USA and/or other countries. All other trademarks are the property of their respective owners. CAUTION: Federal Law (USA) restricts the use of these devices to or by the order of a physician. Before use, consult product labels and Instructions for Use for Indications for Use, Contraindications, Warnings, Precautions, Adverse Events and Directions for Use.


First UK Procedures With New Left Heart Access System Enable More Treatment Options

First UK Procedures With New Left Heart Access System Enable More Treatment Options

Date:

FIRST UK PROCEDURES WITH NEW LEFT HEART ACCESS SYSTEM ENABLE MORE TREATMENT OPTIONS


 (London, UK, January 11, 2017) Baylis Medical’s SupraCross™ RF System was used for the first time in the United Kingdom to allow minimally invasive treatment of 2 patients suffering from symptomatic heart failure that would have otherwise faced open heart surgery. 

Treatment of these heart failure patients often includes cardiac resynchronization therapy (CRT), however for a significant number of patients, the conventional implant technique fails. The only other option has historically been an open surgical procedure which carries additional risks and is not well tolerated by many of these patients. Placing the pacemaker leads into the left heart through the atrial septum offers an alternative minimally invasive approach, however this has been challenging without dedicated tools. 

The SupraCross™ RF System is a novel solution for achieving transseptal access to the left side of the heart from alternative approaches. The first SupraCross™ RF System procedures have been performed by Dr. Paul R. Roberts, M.D., Consultant Cardiologist and Electrophysiologist at the Southampton General Hospital in Hampshire, England.

 “The SupraCross System represents the first dedicated tool for a controlled and effective mechanism of crossing the atrial septum from this alternative approach.” said Dr. Roberts. “This technology represents a major step forward in providing more treatment options for patients that do not have suitable conventional venous anatomy or have not responded to the conventional technique. High risk patients can now avoid major cardiothoracic surgery yet still receive all the benefits of biventricular pacing.”

One of the two patients treated described the significance of this new approach and outcome of the therapy he received from his perspective: “I am delighted that this procedure has meant that I have not had to undergo a major cardiac surgical operation, and I’m already noticing a significant improvement in symptoms with less breathlessness and chest pain.”

The system, developed and manufactured by Baylis Medical in Ontario, Canada, has helped treat many patients in Canada and the United States. After recently receiving CE Mark approval, these 2 patients mark the first outside of North America to benefit from this technology. 

About Baylis Medical Company:
Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology, interventional radiology, and spinal procedures. Our vision is to develop and market innovative medical therapies while Improving the Lives of People Around the World. The company has offices in Montreal and Toronto (Canada), Boston (USA), London (UK) and Munich (Germany). For more information, visit www.baylismedical.com

Media Contact Person:
Laura Mills
Marketing Manager
Baylis Medical Company
Tel: 905.602.4875 ext. 292
lmills@baylismedical.com

About Southampton General Hospital:
Southampton General Hospital is the University Hospital Southampton NHS Foundation Trust’s largest location, with a great number of specialist services based here, ranging from neurosciences and oncology to pathology and cardiology.
Emergency and critical care is provided in the hospital’s special intensive care units, operating theatres, acute medicine unit and emergency department (A&E), as well as the dedicated eye casualty.
Southampton General also hosts outpatient clinics, diagnostic and treatment work, surgery, research, education and training, as well as providing day beds and longer stay wards for hundreds of patients.

PRM-00141 EN J-1,2,3 V-1© Baylis Medical Company Inc., 2016.  SupraCross and the Baylis Medical logo are trademarks and/or registered trademarks of Baylis Medical Company Inc. in the USA and/or other countries.  Patents Pending and/or issued. CAUTION: Federal Law (USA) restricts the use of these devices to or by the order of a physician. Before use, consult product labels and Instructions for Use for Indications for Use, Contraindications, Warnings, Precautions, Adverse Events and Directions for Use.

BAYLIS MEDICAL WINS GLOBAL TRADE AWARD

BAYLIS MEDICAL WINS GLOBAL TRADE AWARD

Date:

For immediate release 

BAYLIS MEDICAL WINS GLOBAL TRADE AWARD 


Montreal, QC – (November 16, 2016) – Baylis Medical has been honoured by the Toronto Region Board of Trade with this year’s Global Trade Award. This distinction recognizes a company with an exciting and viable trade business that is contributing to the Canadian economy by generating export-driven revenue and creating or supporting jobs. 

The award was presented during the 2016 Business Excellence Awards held on November 10th in Toronto. The annual event celebrates companies who have demonstrated exceptional growth, leadership and innovation.  

As noted by Toronto Region Board of Trade President & CEO Jan De Silva, “By successfully growing a business, our 2016 Business Excellence Award winners and nominees are creating opportunities for hundreds of thousands of Canadians. They are role models who are making Toronto one of the most competitive and sought after regions in the world.”  

Kris Shah, President of Baylis Medical Company Inc., accepted the award on behalf of Baylis. 

 “We are honoured  to have been recognized by our peers and declared winner of the 2016 Global Trade Award.” says Shah. “This award reflects the tireless focus and dedication of our highly talented staff, enabling high technology medical devices to improve the lives of patients worldwide.”  

About Baylis Medical Company Inc.: 
Baylis Medical develops and markets high-technology medical devices used in the fields of electrophysiology, interventional cardiology, interventional radiology, and spinal procedures. Our vision is to develop and market innovative medical therapies while Improving the Lives of People Around the World. The company has offices in Montreal and Toronto (Canada), Boston (USA), London (UK) and Munich (Germany). For more information, visit www.baylismedical.com. 

Media Contact Person: 
Luc Desaulniers 
Senior Marketing Communications Specialist 
Baylis Medical Company 
Tel: 514-488-9801 
ldesaulniers@baylismedical.com 
www.baylismedical.com 

Baylis Medical expands its presence with a new office in Germany

Date:

For immediate release

BAYLIS MEDICAL EXPANDS ITS PRESENCE WITH NEW OFFICE IN GERMANY

Montreal, QC – (September 28, 2016) – Baylis Medical Company Inc., a leading supplier of high-technology medical devices, is pleased to announce the opening of its new office in Munich, Germany. As part of Baylis Medical’s continued expansion, the new office will serve the company’s growing European customer base. 

The addition of the Munich office complements the company’s existing offices in London, Boston, Toronto, and Montreal.

“We’re excited to continue to expand our global presence by establishing roots in Germany. This new location allows Baylis Medical to offer local support to our growing customer base. It is a testament to our continued success in Europe” said Kris Shah, President of Baylis Medical. The company plans to recruit additional members for the regional team in the near future.

“Choosing Munich as part of its strategic expansion in Europe shows that innovative companies like Baylis Medical value the outstanding position Bavaria enjoys internationally, particularly in the field of medical technologies” said Frédéric Arsenault, Project Manager Business & Technology, State of Bavaria Quebec Office.

Baylis Medical’s new office is located at the following address:

BAYLIS Medical (Deutschland) GmbH

 Landshuter Allee 8-10

80637 München

Germany


About Baylis Medical Company Inc.:

Baylis Medical develops and markets high-technology medical devices used in the fields of electrophysiology, interventional cardiology, interventional radiology, and spinal procedures. Our vision is to develop and market innovative medical therapies to Improve the Lives of People Around the World. The company has offices in Montreal and Toronto (Canada), Boston (USA), London (UK) and Munich (Germany). For more information, visit www.baylismedical.com.


Media Contact Person:

Luc Desaulniers

Senior Marketing Communications Specialist

Baylis Medical Company

Tel: 514-488-9801

ldesaulniers@baylismedical.com

www.baylismedical.com

 

                                                                               —30—




© Copyright Baylis Medical Company Inc., 2016. The Baylis Medical logo is a trademark or registered trademark of Baylis Medical Company Inc. in the United States of America and/or other countries.

Baylis Medical pledged $300,000 toward Waterloo University Engineering

Date:

For immediate release


MEDICAL PLEDGES $300,000 TOWARDS FUTURE INNOVATION BY UNIVERSITY OF WATERLOO ENGINEERING STUDENTS

 

(Montreal, 4 May 2016) Baylis Medical is donating $300,000 to support future innovations by University of Waterloo systems design and biomedical engineering students.

The funding will be used for the Baylis Medical Student Garage to be located in University of Waterloo’s Engineering 7 building currently under construction.

The 1,010 square foot garage, to be the largest student garage in the Engineering 7 building, will provide the biomedical engineering students with dedicated space to work on their senior year projects.

“The Baylis Medical Student Garage will be well used by our systems design and biomedical engineering students to create the next generation of medical devices,” said Pearl Sullivan, acting dean of Waterloo Engineering. “We are grateful to Baylis Medical for supporting our Educating the Engineer of the Future campaign. We are proud to name this exciting space after such an innovative company that leads the way in high-technology medical devices. We look forward to witnessing future innovations in this field by our students.”

Based on the success of the student team garages in the Faculty’s Engineering 5 building, the Baylis Medical Student Garage will provide systems design and biomedical engineering students with opportunities to create and innovate.

“Baylis is proud to be associated with one on the most innovative universities in North America. The Baylis Medical Student Garage will further the development of knowledge and resources toward educating the biomedical engineers of the future” says Kris Shah, President of Baylis Medical Company Inc. and a Waterloo Engineering graduate.

Baylis Medical’s pledge is one of the many financial contributions the company has made to the academic community.

About Baylis Medical Company:

Baylis Medical develops and markets high-technology medical devices used in the fields of electrophysiology, interventional cardiology, interventional radiology, and spinal procedures. Our vision is to develop and market innovative medical therapies while Improving the Lives of People Around the World. The company has offices in Montreal and Toronto (Canada), Boston (USA), and London (UK). For more information, visit www.baylismedical.com.

 Media Contact Person:

Luc Desaulniers
Senior Marketing Communications Specialist
Baylis Medical Company
Tel: 514-488-9801
ldesaulniers@baylismedical.com
http://www.baylismedical.com
 
 

                                                                              —30—


© Copyright Baylis Medical Company Inc., 2016. The Baylis Medical logo is a trademark or registered trademark of Baylis Medical Company Inc. in the United States of America and/or other countries.


Ontario investing $4.22 million to expand Baylis Medical R&D and manufacturing operations.

Date:

For immediate release


ONTARIO INVESTING $4.22 MILLION TO EXPAND BAYLIS MEDICAL R&D AND MANUFACTURING OPERATIONS IN MISSISSAUGA



(Montreal, March 17, 2016) —Ontario is partnering with Baylis Medical Company to support an expansion project at the company’s Mississauga research and development (R&D) and manufacturing facilities, which will create 84 new jobs that will be added to the 194 current jobs.

Through the province’s Jobs and Prosperity Fund, specifically under the New Economy Stream, Ontario will provide a conditional grant of up to $4.22 million to support the company’s expansion into a new advanced facility, and its plan to almost double its exports over the course of this investment.

Expansion and additional manufacturing capabilities will help Baylis Medical reduce costs and bolster the company’s position to enable continued growth of its core business. Investments in talent will support the production of three new product lines and help the company reach new international markets, including Australia, Brazil, China and South Korea. The $32.5 million overall investment being made towards the new project will significantly increase the company’s cleanrooms and R&D spaces.

“The government’s number-one priority is growing the economy and creating jobs.” said  Hon Brad Duguid, Ontario Minister of Economic Development, Employment and Infrastructure. “The government’s support for Baylis Medical will help them expand facilities, ramp up their important research and development work and leverage new and innovative technologies. These efforts will allow Baylis Medical to strengthen their exports and significantly increase global competitiveness.” 

“Today’s announcement is great news for Mississauga. I’m delighted that our government continues to invest in our life sciences sector by supporting innovative companies like Baylis Medical that generate significant economic activity, both at home and abroad.”
— Amrit Mangat, MPP for Mississauga—Brampton South

“We are pleased to be partnering with Ontario on this expansion project. Our company has a track record for developing and commercializing advanced medical devices.” said Kris Shah, President, Baylis Medical Company. “This new facility will give us the space to increase production and hire additional resources to expand our portfolio of innovative products.  This strategic partnership will help us compete and succeed globally.”


About Baylis Medical Company:
Baylis Medical develops and markets high-technology medical devices used in the fields of electrophysiology, interventional cardiology, interventional radiology, and spinal procedures. Our vision is to develop and market innovative medical therapies while Improving the Lives of People Around the World. The company has offices in Montreal and Toronto (Canada), Boston (USA), and London (UK). For more information, visit www.baylismedical.com.


Media Contact Person:
Luc Desaulniers, 
Senior Marketing Communications Specialist 
Baylis Medical Company
Tel: 514-488-9801
ldesaulniers@baylismedical.com
http://www.baylismedical.com




                                                                              —30—




© Copyright Baylis Medical Company Inc., 2016. Baylis Medical Company Inc. The Baylis Medical logo is a trademark or registered trademark of Baylis Medical Company Inc. in the United States of America and/or other countries.

Baylis Medical in partnership with CANet brings new possibilities to patients suffering from cardiac arrhythmias

Date:

For immediate release


BAYLIS IN PARTNERSHIP WITH CANET BRINGS NEW POSSIBILITIES TO PATIENTS SUFFERING FROM CARDIAC ARRHYTHMIAS


(Montreal, February 15, 2016) Baylis Medical’s new streamlined transseptal system, licensed in Canada, comprised of a radiofrequency active pigtail guidewire and a steerable sheath, brings new possibilities to patients suffering from heart failure.

Dr. Jaimie Manlucu, treating physician, CANet Investigator, and member of the Arrhythmia Service at London Health Sciences in London, Ontario noted that a significant number of heart failure patients who are candidates for cardiac resynchronization therapy (CRT) often have suboptimal outcomes with conventional implant techniques.  Placing CRT pacing wires into the left heart through the atrial septum is a promising alternative approach, but can be challenging without dedicated tools.

“This innovative transseptal system from Baylis Medical is the first commercially available  apparatus that optimizes transseptal access from an alternate superior approach,” said Dr. Manlucu, “Streamlining the transseptal aspect of the implant procedure allows us to provide this therapy in a reliably safe and efficient way.”

“We are pleased to have developed this streamlined access method to the left atrium that enables physicians to deliver their therapies.” said Kris Shah, president of Baylis Medical. “Access to CANet’s leading-edge network of investigators allows us to validate our therapies and move them to the market – and bring relief to patients, faster.”

“Partnerships with Canadian companies, like Baylis Medical, are integral to developing and commercializing potentially lifesaving therapies,” said Dr. Anthony Tang, CEO and Scientific Director of CANet. “By working together we will develop cutting edge technologies and become a powerful engine of innovation for the arrhythmia field.”

These new devices developed and manufactured by Baylis Medical in Ontario, Canada were made possible in part by a repayable contribution through the Federal Economic Development Agency for Southern Ontario’s Advanced Manufacturing Fund.


About CANet:
The Cardiac Arrhythmia Network of Canada is a not-for-profit organization dedicated to transforming Canada’s arrhythmia health care system through integrated trans-disciplinary research and development. The network’s strategy is to invent, prove, and implement innovative solutions to enable patients to take ownership and co-manage their arrhythmia health. CANet is funded by the federal government's Networks of Centres of Excellence (NCE), Canada's flagship science and technology program.

About Baylis Medical Company:
Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology, interventional radiology, and spinal procedures. Our vision is to develop and market innovative medical therapies while Improving the Lives of People Around the World. The company has offices in Montreal and Toronto (Canada), Boston (USA), and London (UK). For more information, visit www.baylismedical.com.

Media Contact Person:
Luc Desaulniers, 
Communications Associate, 
Baylis Medical Company
Tel: 514-488-9801 ldesaulniers@baylismedical.com
http://www.baylismedical.com






© Copyright Baylis Medical Company Inc., 2016. Baylis Medical Company Inc. The Baylis Medical logo is a trademark or registered trademark of Baylis Medical Company Inc. in the United States of America and/or other countries. Before use, consult product labels and inserts for any indications, contraindications, hazards, warnings, cautions, and instructions for use. 

CAUTION: Federal Law (USA) restricts the use of this device to or by the order of a physician. 



Baylis Medical partners with Medtronic on innovative spinal tumor ablation technology.

Baylis Medical partners with Medtronic on innovative spinal tumor ablation technology.

Date:

For immediate release

BAYLIS MEDICAL PARTNERS WITH MEDTRONIC ON INNOVATIVE SPINAL TUMOR ABLATION TECHNOLOGY 


(Montreal, Canada, January 13, 2016) 

Baylis Medical Company announces a partnership with Medtronic (NYSE: MDT) to enhance patient access to a highly innovative spinal tumour ablation system which recently received U.S. Food and Drug Administration (FDA) 510(k) clearance. 

For physicians who treat patients with painful spine metastases, the OsteoCool™ RF Ablation System is the only cooled radiofrequency (RF) ablation technology that offers simultaneous, dual-probe capabilities – providing procedural flexibility and predictable, customized treatment.  Cooled RF ablation uses targeted high-frequency energy to ablate tumors.

Medtronic acquired the OsteoCool technology and associated intellectual property from Baylis Medical on December 16, 2015 and partnered with the company to further innovate the System.  Terms of the acquisition were not disclosed.

"The OsteoCool System expands our Pain Therapies portfolio,” said Julie Foster, general manager and vice president of the Pain Therapies business in the Neuromodulation division, which is part of the Restorative Therapies Group at Medtronic.  "Our customers treat patients with Kyphon® Balloon Kyphoplasty who also have painful spinal metastases.  The OsteoCool system gives physicians a way to treat that pain in a single procedure with a familiar, minimally invasive technique.” 

“We’re pleased to be partnering with Medtronic to improve the treatment of patients suffering from spinal metastases," said Kris Shah, president of Baylis Medical.  "Our company has a long, established track record of developing innovative clinical solutions.  We are excited that this partnership with Medtronic will enhance patient access to our novel spinal tumor ablation technology.”

About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 85,000 people worldwide, serving physicians, hospitals and patients in approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

About Baylis Medical Company
Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology, interventional radiology, and spinal procedures. Our vision is to develop and market innovative medical therapies while Improving the Lives of People Around the World. The company has offices in Montreal and Toronto (Canada), Boston (USA), and London (U.K.). For more information, visit www.baylismedical.com

Media Contact Person:
Luc Desaulniers, 
Communications Associate, 
Baylis Medical Company
Tel: 514-488-9801 ldesaulniers@baylismedical.com
http://www.baylismedical.com

Kyphon Balloon Kyphoplasty incorporates technology developed by Gary K. Michelson, M.D.

-30-

Medtronic OsteoCool Demonstration: Play video

Baylis Medical Company unveils its new 70,000 Sq Ft facility in Mississauga.

Date:

For immediate release

 

Baylis Medical Company unveils its new 70,000 Sq Ft facility in Mississauga.  

(Mississauga, Canada, December 7, 2015) Baylis Medical Company is proud to announce the opening of their newest research, development, and production facility in Mississauga, Ontario. The expansion into the state-of-the-art, 70,000-sq. ft. facility more than doubles the company’s cleanroom and R&D space.

“I can’t overstate the impact that this new facility will have on our core business of developing high-technology medical devices,” said Kris Shah, President of Baylis Medical. “With the increased space and resources, the opportunity for technological advancement and company growth is extraordinary. We are now better able to pursue our mission of Improving the Lives of People Around the World.” “Today’s grand opening showcases the strength of Canada’s high-tech medical sector and the future of manufacturing in southern Ontario,” stated the Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development. “I look forward to seeing the continued growth of Baylis and other innovative businesses that create good quality jobs and wealth for all Canadians.” Baylis Medical Company will unveil the new facility at 2775 Matheson Blvd. East in an Opening Ceremony to be held on December 7, 2015.

The expansion, including new and improved manufacturing capabilities, was made possible, in part, by a repayable contribution from FedDev Ontario through the Advanced Manufacturing Fund.

About Baylis Medical Company

Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology, interventional radiology, and spinal procedures. Our vision is to develop and market innovative medical therapies while Improving the Lives of People Around the World. The company has offices in Montreal and Toronto (Canada), Boston (USA), and London (U.K.). For more information, visit www.baylismedical.com

Media Contact Person:
Luc Desaulniers, Communications Associate,
Baylis Medical Company
Tel: 514-488-9801 ldesaulniers@baylismedical.com
http://www.baylismedical.com

Baylis Medical thrives with support of Greater Boston community; moves to larger offices

Date:

FOR IMMEDIATE RELEASE

 

Baylis Medical thrives with support of Greater Boston community; moves to larger offices

 

Burlington, Mass. (September 10, 2015) – Baylis Medical is pleased to announce their relocation to a larger office in Burlington, Mass. After its initial arrival to the Greater Boston area in 2013, Baylis Medical’s continued success has surpassed the available space allocation and was required to relocate to a new office site.

Baylis Medical’s expanding US sales force and product line has warranted this relocation. “Consequent with Baylis Medical policies, our new location includes many environmentally friendly features, and relies largely on natural daylight”. comments Marie-Claude Jacques, National Sales Manager USA.

Baylis Medical’s new office is located at the following address:

78 Blanchard Road, Suite 204

Burlington, MA 01803

 

A ribbon-cutting ceremony was held today to officially open the new facility.

 

About Baylis Medical

Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology, interventional radiology, and spinal procedures. The company’s core expertise lies in electrosurgical systems that are used to deliver various therapeutic treatments. The company has offices in Montreal, Toronto, Vancouver, Boston (USA) and, London (U.K.). For more information, visit www.baylismedical.com

 

Contact

Luc Desaulniers
Communications Associate
Baylis Medical Company
Tel: 514-488-9801
ldesaulniers@baylismedical.com
http://www.baylismedical.com

m

Physicians now have an additional option for visualization during transseptal procedures

Physicians now have an additional option for visualization during transseptal procedures

Date:

FOR IMMEDIATE RELEASE

Physicians now have an additional option for visualization during transseptal procedures

Boston, USA (May 27th, 2015) – With the introduction of the DuoMode™ cable, physicians can now visualize their transseptal needle on their mapping system prior to doing a transseptal puncture.

The transseptal procedure is a challenging, minimally invasive procedure used to cross the septum of the heart. Cardiac electrophysiologists use their mapping systems to electrically map the heart, which in turn guides their ablation procedures.

With the use of the new DuoMode cable, physicians can now connect their transseptal needle to their mapping system. This provides a clear indication of the position of the tip of the needle within the map of the heart.

Dr. Rodney Horton of the Texas Cardiac Arrhythmia Institute is a world leader in the movement to reduce fluoroscopy exposure to patients and attending medical staff during ablation procedures. He has presented at various conferences on this new technique that he pioneered and he is sought out to teach other physicians on the method. Dr Horton states: “The DuoMode cable allows me to visualize the transseptal puncture needle on my mapping system. This important positioning information can help reduce fluoroscopy usage and provide additional guidance prior to puncturing the atrial septum.

Baylis Medical is committed to innovating in the field of left heart access. The DuoMode cable is the latest addition to the company’s leading edge left heart access technologies.

About Baylis Medical

Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology, interventional radiology, and spinal procedures. The company’s core expertise lies in electrosurgical systems that are used to deliver various therapeutic treatments. The company has offices in Montreal, Toronto, Vancouver, Boston (USA) and, London (U.K.). For more information, visit www.baylismedical.com

Contact

Luc Desaulniers
Communications Associate
Baylis Medical Company
Tel: 514-488-9801
ldesaulniers@baylismedical.com
http://www.baylismedical.com

###

©-Copyright Baylis Medical Company Inc., 2015 Baylis Medical Company Inc. reserves the right to change specifications or to incorporate design changes without notice and without incurring any obligation relating to equipment previously manufactured or delivered. DuoMode is a trademark or registered trademark of Baylis Medical Company Inc. in the United States of America and/or other countries. Before use, consult product labels and inserts for any indications, contraindications, hazards, warnings, cautions and instructions for use. CAUTION: Federal Law (USA) restricts the use of this device to or by the order of a physician.

Baylis Medical Expands European Reach with New Office Opening in London, UK

Date:

FOR IMMEDIATE RELEASE

Baylis Medical Expands European Reach with New Office Opening in London, UK

Watford, United Kingdom (November 24th, 2014) – Baylis Medical, a leading supplier of high-technology interventional cardiology and radiology products, is pleased to announce the official opening of its new office in Watford, UK, on the outskirts of London. The opening of the Watford office is a part of Baylis Medical’s European expansion project.

Baylis Medical’s business in Europe has grown substantially with an expanding sales force, strong distribution partnerships and the successful launch of several new products. The Watford office expansion was warranted by this growth. “The new office represents our commitment towards our continued growth in the European market through strengthened operational capabilities, enhanced technical support, and direct sales in the UK, Germany and France.” said Frank Baylis, President.

Found within the life sciences “Golden Triangle”, the new office will also bring in new opportunities for Baylis Medical. “The Golden Triangle is a hub of bio-tech activities, and we are looking forward to tapping into the local expertise as we continue to expand our presence,” noted Mr. Baylis. “We will be looking to recruit more members to our team in the near future.”

“Congratulations to Baylis Medical on the opening of its expanded office,” said Paul Witcombe, Enterprise & Innovation Manager at the Hertfordshire Local Enterprise Partnership (LEP), a regional business development firm aiding businesses to tap into the area’s key resources. “We are pleased that the company has chosen Watford as the home for its European operations. The company’s portfolio of products, ranging from cardiology to radiology, is a great addition to our life sciences community, and we are confident that Watford is the best place for Baylis Medical to continue to grow its business.”

Baylis Medical’s new office is located at the following address:
Suite 11, Building 6
Croxley Green Business Park
Watford, Hertfordshire
WD18 8YH
United Kingdom

 
About Baylis Medical
Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology and interventional radiology. The company’s core expertise lies in electrosurgical systems that are used to provide access to various parts of the cardiovascular system. The company has offices in Montreal, Toronto, Vancouver, Boston (USA) and, London (U.K.). For more information, visit www.baylismedical.com.  
 
Contact
Luc Desaulniers

Communications Associate

Baylis Medical Company

Tel: 514-488-9801

ldesaulniers@baylismedical.com

http://www.baylismedical.com

###

© Copyright Baylis Medical Company Inc., 2014 Baylis Medical Company Inc. reserves the right to change specifications or to incorporate design changes without notice and without incurring any obligation relating to equipment previously manufactured or delivered.

 First European Experience with Innovative Guidewire at St George’s Hospital London, UK

First European Experience with Innovative Guidewire at St George’s Hospital London, UK

Date:

FOR IMMEDIATE RELEASE

First European Experience with Innovative Guidewire at St George’s Hospital London, UK

 London, United Kingdom (July 1st, 2014) – The first cases using the ProTrack™ Pigtail Wire in Europe were performed last month at St George’s Hospital in London. The ProTrack™ Pigtail Wire is used during the transseptal procedure, a challenging minimally  invasive technique used to cross the septum of the heart.

 Dr. Riyaz Kaba, Electrophysiologist at St George’s Hospital, explains: “The ProTrack™ Pigtail Wire worked very well in our initial experience. The design combines a strong core in the body of the wire with a soft, curled tip.  The strong core provides the strength needed to cross a challenging septum, while the soft tip is atraumatic to the left atrium.”

 In certain patients, physicians are faced with highly resistant cardiac tissue. In such instances, physicians are normally required to apply strong pressure on catheters and guidewires, which increases the risk of inadvertent perforation. The ProTrack™ Pigtail Wire is designed to minimize this risk by providing more control.  

 The transseptal procedure is commonly part of atrial fibrillation ablation procedures and other emerging cardiac interventions, such as left atrial appendage occlusion and mitral valve repair. It is a challenging and specialized technique used to place treatment catheters into to the left atrium of the heart.

 The ProTrack™ Pigtail Wire, designed specifically for the transseptal procedure, incorporates a stiff body with a soft curling pigtail-like tip. The purpose of this dual design is to provide the support needed to advance any transseptal sheath into the left atrium while reducing the risk of inadvertent perforation.

 About Baylis Medical

Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology and interventional radiology. The company’s core expertise lies in electrosurgical systems that are used to deliver various therapeutic treatments. The company has offices in Montreal, Toronto, Vancouver, Boston (USA) and, London (U.K.). For more information, visit www.baylismedical.com.  

 Contact

Luc Desaulniers
Communications Associate
Baylis Medical Company
Tel: 514-488-9801
ldesaulniers@baylismedical.com
http://www.baylismedical.com

###

 

©-Copyright Baylis Medical Company Inc., 2014 Baylis Medical Company Inc. reserves the right to change specifications or to incorporate design changes without notice and without incurring any obligation relating to equipment previously manufactured or delivered. ProTrack™ is a trademark or registered trademark of Baylis Medical Company Inc. in the United States of America and/or other countries.

Before use, consult product labels and inserts for any indications, contraindications, hazards, warnings, cautions and instructions for use.

CAUTION: Federal Law (USA) restricts the use of this device to or by the order of a physician.

Randomized Controlled Trial Demonstrates Radiofrequency Transseptal Needle Provides Added Benefits over Conventional Needle

Randomized Controlled Trial Demonstrates Radiofrequency Transseptal Needle Provides Added Benefits over Conventional Needle

Date:

FOR IMMEDIATE RELEASE

Randomized Controlled Trial Demonstrates Radiofrequency Transseptal Needle Provides Added Benefits over Conventional Needle

Montreal, Canada (September 27, 2013) – The results of a randomized controlled trial comparing the safety and effectiveness of the radiofrequency  NRG® Transseptal Needle to a conventional mechanical needle were published this month in The Journal of the American Heart Association. Conducted by electrophysiologists at the University of California, San Francisco, the study shows that the radiofrequency  NRG® needle was successful in completing the transseptal puncture in a number of procedures where the conventional needle failed to do so. There was no difference observed in the rate of adverse events. The radiofrequency NRG® needle also significantly reduced median transseptal procedure time. A further benefit was seen in that the radio frequency NRG® needle produced less grossly visible plastic shavings (0%) compared to the mechanical needle (33.3%).

The transseptal procedure is commonly part of atrial fibrillation ablation cases. It is a challenging and specialized procedure used to gain access to the left atrium of the heart.

Dr. Gregory Marcus, Director of Clinical Research for the UCSF Division of Cardiology, and senior author of the study, believes the NRG® needle improves transseptal procedure efficacy and efficiency: “Previous observational studies have suggested that radiofrequency assisted transseptal puncture may provide superior benefits over a regular mechanical needle. Our study provides the first randomized clinical evidence to suggest increased effectiveness and efficiency of the RF needle.”

This randomized, controlled trial included 72 patients undergoing cardiac catheter ablation procedures with a planned transseptal puncture. Subjects were randomized on a 1:1 basis to receive transseptal puncture with either a radiofrequency needle or a conventional needle. The median time to achieve transseptal left atrial access was 68% shorter using the NRG® needle as compared to the conventional needle (2.3 minutes versus 7.3 minutes, on an intention-to-treat basis). Failure to achieve transseptal access with the assigned needle did not occur with the NRG® needle, whereas the conventional needle failed on ten occasions (27.8%). In these 10 failed instances, subsequent crossover to the NRG® needle enabled a successful transseptal procedure. Ex vivo preprocedural testing found that the conventional needle produced visible plastic shavings in one-third of the cases whereas the NRG® needle did not produce any such plastic shavings.

About Baylis Medical

Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology and interventional radiology. The company’s core expertise lies in electrosurgical systems that are used to deliver various therapeutic treatments. The company has offices in Montreal, Toronto, Vancouver, Boston (USA), London (U.K.). For more information, visit www.baylismedical.com.

Contact

Luc Desaulniers
Communications  Associate
Baylis Medical Company
Tel: 514-488-9801
ldesaulniers@baylismedical.com
http://www.baylismedical.com

###

©-Copyright Baylis Medical Company Inc., 2013 Baylis Medical Company Inc. reserves the right to change specifications or to incorporate design changes without notice and without incurring any obligation relating to equipment previously manufactured or delivered. NRG® is a trademark or registered trademark of Baylis Medical Company Inc. in the United States of America and/or other countries.

Before use, consult product labels and inserts for any indications, contraindications, hazards, warnings, cautions and instructions for use. CAUTION: Federal Law (USA) restricts the use of this device to or by the order of a physician.

Baylis Medical strengthens U.S. presence with new office in Greater Boston

Baylis Medical strengthens U.S. presence with new office in Greater Boston

Date:

FOR IMMEDIATE RELEASE

Baylis Medical strengthens U.S. presence with new office in Greater Boston

Burlington, Mass. – (May 21, 2013) – Baylis Medical, a leading supplier of high-technology interventional cardiology and radiology products, is pleased to announce the official opening of its new offices in Burlington, Mass. The opening of the Boston-area office is a part of Baylis Medical’s ongoing global expansion project. Baylis Medical currently employs 200 employees globally and plans to hire additional employees this year.

Baylis Medical’s business has grown substantially over the past 24 months with an expanding sales force and the successful launch of several new products. The Boston office expansion was warranted by this growth. “The new office represents our commitment towards our continued growth in the U.S. market through direct sales, strengthened operational capabilities and enhanced technical support,” said Frank Baylis, President.

The new office will also bring in new opportunities for Baylis Medical. “Boston is a hub of medical device activities, and we are looking forward to tapping into the local expertise as we continue to expand our presence,” noted Baylis. “We will be looking to recruit more members to our team in the near future.”

“I welcome Baylis Medical to Massachusetts and look forward to them strengthening our innovation economy by creating jobs and economic development,” said Governor Deval Patrick.

Through the Massachusetts Life Sciences Center, Massachusetts is investing $1 billion over 10 years in the growth of the state’s life sciences supercluster. These investments are being made under the Massachusetts Life Sciences Initiative, proposed by Governor Patrick in 2007, and passed by the State Legislature and signed into law by Governor Patrick in 2008.

Massachusetts officials first met with Baylis Medical at the AdvaMed 2012 conference in Boston last October. “Congratulations to Baylis Medical on the opening of its first U.S. office,” said Susan Windham-Bannister, Ph.D., President & CEO of the Massachusetts Life Sciences Center (MLSC). “We are pleased that the company has chosen Massachusetts as the home for its U.S. operations. The company\'s portfolio of products, ranging from chronic pain management to radiology, are a great addition to our life sciences community, and we are confident that Massachusetts is the best place for Baylis Medical to continue to grow its business.”

“Burlington is pleased to welcome Baylis and its employees to town, and we hope they fully immerse themselves in all that Burlington has to offer,” said Massachusetts State Representative Kenneth I. Gordon. “The opening of Baylis Medical’s location demonstrates the recognition of Burlington as an important high tech center.”

“Baylis Medical has discovered what scores of other medtech companies now know – Massachusetts is a great place to establish a foothold in the American medical market,” said Tom Sommer, President of the Massachusetts Medical Device Industry Council (MassMEDIC). “We welcome the expansion of yet another Canadian medical device company in Massachusetts.”

“I join the Governor in welcoming Baylis Medical to Massachusetts,” said Tom Gradel, Acting Director of the Massachusetts Office of International Trade & Investment. “Baylis Medical will join a broad and deep ecosystem in the global hub of life sciences.”

Baylis Medical’s new office is located at the following address:
 
50 Mall Road
Suite G18
Burlington, MA 01803
 
About Baylis Medical
Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology and interventional radiology. The company’s core expertise lies in electrosurgical systems that are used to deliver various therapeutic treatments. The company has offices in Montreal, Toronto, Vancouver, London, U.K. and Boston, Mass. For more information, visit www.baylismedical.com.  
 
About the Massachusetts Life Sciences Center
The Massachusetts Life Sciences Center (MLSC) is a quasi-public agency of the Commonwealth of Massachusetts tasked with implementing the Massachusetts Life Sciences Act, a 10-year, $1-billion initiative that was signed into law in June of 2008. The MLSC’s mission is to create jobs in the life sciences and support vital scientific research that will improve the human condition. This work includes making financial investments in public and private institutions that are advancing life sciences research, development and commercialization as well as building ties among sectors of the Massachusetts life sciences community. For more information, visit www.masslifesciences.com.
 

Luc Desaulniers             
Communications Associate       
Baylis Medical Company       
Tel : 514-488-9801        
ldesaulniers@baylismedical.com   

Angus McQuilken
Vice President for Communications and Marketing
Massachusetts Life Sciences Center
Tel : 617-921-7749
amcquilken@masslifesciences.com

This announcement is not intended to be a commercial endorsement by the MLSC of any products or services provided or developed by the entities referenced in this release.

###
 

Largest Case Series of New Radiofrequency Guidewire Shows Positive Results

Largest Case Series of New Radiofrequency Guidewire Shows Positive Results

Date:

FOR IMMEDIATE RELEASE

Largest Case Series of New Radiofrequency Guidewire Shows Positive Results

Montreal, Canada – (August 25, 2012) – Published in this month’s issue of the Journal of Vascular and Interventional Radiology is the largest case series to date using the PowerWireTM RF Guidewire. The retrospective study, published by Dr. Marcelo Guimaraes and colleagues at the Medical University of South Carolina (MUSC), describes the experience and outcomes of using the PowerWire™ RF Guidewire to cross chronic, symptomatic central venous occlusions (CVOs) that are resistant to standard techniques. The PowerWire™ RF Guidewire was successful at crossing 100% of the occlusions in 42 patients.

Successful crossing of lesions using the PowerWireTM RF Guidewire was achieved in 100% of cases with a global (major) complication rate of 2.3%. Forty of 42 patients were symptom-free and were able to continue dialysis at 6 and 9 months follow up. On the PowerWire™ RF Guidewire’s performance, Dr. Guimaraes comments: “The results of this technique are impressive. Because we use radiofrequency wire recanalization only after failure of conventional endovascular techniques, the patients would have either been left untreated or the alternative would be an open chest vascular by-pass surgery.”

A total of 43 recanalizations were performed in 42 patients using the PowerWireTM RF Guidewire between January 2008 and December 2011. In all patients, previous attempts at recanalization with conventional techniques and devices had failed. The authors conclude by advocating the use of the PowerWireTM RF Guidewire in select cases of chronic, symptomatic CVOs that are resistant to crossing with standard endovascular techniques. Central venous occlusions may be present in up to 38% of patients with a centrally placed dialysis catheter, and up to 24% of these occlusions cannot be crossed using conventional techniques. These patients have few treatment options and are often living with painful symptoms including swelling of the face, neck, and arms.

About Baylis Medical

Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology and interventional radiology. The company’s core expertise lies in electrosurgical systems that are used to deliver various therapeutic treatments. The company has offices in Montreal, Toronto, Vancouver, London (U.K.). For more information, visit www.baylismedical.com.

Contact

Luc Desaulniers
Communications Associate
Baylis Medical Company
Tel: 514-488-9801
ldesaulniers@baylismedical.com
http://www.baylismedical.com

###

 

 

©-Copyright Baylis Medical Company Inc., 2013 Baylis Medical Company Inc. reserves the right to change specifications or to incorporate design changes without notice and without incurring any obligation relating to equipment previously manufactured or delivered. PowerWire™ is a trademark or registered trademark of Baylis Medical Company Inc. in the United States of America and/or other countries.


Before use, consult product labels and inserts for any indications, contraindications, hazards, warnings, cautions and instructions for use. CAUTION: Federal Law (USA) restricts the use of this device to or by the order of a physician.

Baylis Medical Launches NRG® Transseptal Needle with Radiopaque Marker

Baylis Medical Launches NRG® Transseptal Needle with Radiopaque Marker

Date:

FOR IMMEDIATE RELEASE

Baylis Medical Launches NRG® Transseptal Needle with Radiopaque Marker

Stanford- California (June 12, 2012) – Baylis Medical is pleased to announce the release of its new radiofrequency NRG® Transseptal Needle with radiopaque marker. The radiopaque marker allows physicians to precisely visualize the tip of the needle prior to puncturing the septum of the heart during the transseptal puncture procedure.

The transseptal puncture procedure is used to gain access to the left side of the heart in order to perform various treatments. The past few years have seen a tremendous growth in the number of transseptal procedures performed as more cardiac treatments require this minimally invasive technique. These cardiac treatments include: atrial fibrillation ablation, mitral valve repair and left atrial appendage occlusion.

The transseptal puncture is a challenging procedure with the potential for serious adverse events if the puncture is unintentionally made in the incorrect location. Now, by using the radiofrequency NRG® Transseptal Needle with radiopaque marker, physicians can more readily locate the tip of the needle. This allows them to confidently guide the needle throughout the transseptal procedure. 

Dr. Al-Ahmad of Stanford Hospital and Clinics sees important value in this new feature: “In performing the transseptal procedure, there is potential of inadvertently puncturing in the wrong location. The radiopaque tipped needle can help doctors in doing in the procedure by allowing them to visualize the very tip of the needle. Very simply, I like to see where I am.”  

About Baylis Medical
Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology and interventional radiology. The company’s core expertise lies in electrosurgical systems that are used to deliver various therapeutic treatments. The company has offices in Montreal, Toronto, Vancouver, London, U.K. and Boston, Mass. For more information, visit www.baylismedical.com.  

Contact
Luc Desaulniers
Communications Associate
Baylis Medical Company
Tel: 514-488-9801
ldesaulniers@baylismedical.com
http://www.baylismedical.com

 

Before use, consult product labels and inserts for any indications, contraindications, hazards, warnings, cautions and instructions for use. CAUTION: Federal Law (USA) restricts the use of this device to or by the order of a physician.

Baylis Medical Executives Win Entrepreneur Of The Year Award

Baylis Medical Executives Win Entrepreneur Of The Year Award

Date:

FOR IMMEDIATE RELEASE

Baylis Medical Executives Win Entrepreneur Of The Year Award

Montreal - Canada (October 10, 2011) – During a ceremony held last Friday, Frank Baylis, President of Baylis Medical Inc. and Kris Shah, Executive Vice President & Chief Technology Officer, were named Ernst & Young’s 2011 Quebec Health Sciences Entrepreneurs Of The Year.

The Entrepreneur Of The Year Award recognizes Frank Baylis and Kris Shah for their longstanding success in the Canadian medical device industry. In Baylis Medical’s formative years, the company’s main operations consisted of the importation and distribution of medical devices into the Canadian market. From this beginning, the company has transformed itself into a developer and manufacturer of innovative, high-technology medical devices that are sold around the world. “Though the award was in our personal names, the reality is that any such victory is really the result of a great team effort. Kris and I are lucky and honoured to be surrounded by an outstanding team of engineers, technical staff, sales people, production staff, and more, who all contribute to the success of the company” said Frank Baylis.

A strong commitment to delivering innovative products has earned the company not only commercial success, but the interest from large medical device conglomerates. Baylis Medical presently has development partnerships with various major medical device companies.

This prestigious award falls concurrently on Baylis Medical’s 25th anniversary.

The Entrepreneur Of The Year awards honor the spirit and contribution of entrepreneurs here and around the world. Nominees are reviewed by an independent judging panel, which is composed of several distinguished business leaders and previous award recipients. The 2011 Quebec region judging panel consisted of Jean Cloutier, Vice President, Operations and Finance, Outdoor Gear Canada (OGC); Jean Gattuso, President and Chief Executive Officer, A. Lassonde Inc.; Nina Gupta, President, Greenlite Lighting Corporation; Andrée-Lise Méthot, Founder and Senior Partner, Cycle Capital Management; Pascal Pilon, President and CEO, Averna; Alexandre Taillefer, Partner, XPND Capital; Étienne Veilleux, President and CEO, Distech Controls Inc.

About Baylis Medical

Baylis Medical develops and markets high-technology medical devices used in the fields of Interventional Cardiology and Interventional radiology. The company’s core expertise lies in electrosurgical systems that are used to deliver various therapeutic treatments. The company has offices in Montreal, Toronto, Vancouver, and London, U.K. For more information, please visit www.baylismedical.com.  

Contact

Luc Desaulniers
Communications Associate
Baylis Medical Company
Tel: 514-488-9801
ldesaulniers@baylismedical.com
http://www.baylismedical.com

###

Baylis Medical continues its growth in interventional cardiology

Baylis Medical continues its growth in interventional cardiology

Date:

FOR IMMEDIATE RELEASE

Baylis Medical continues its growth in interventional cardiology, interventional radiology and in the Canadian distribution business

(Montreal, 13 October 2009) Last week we announced the news that Kimberly Clark had purchased the pain management business of Baylis Medical. While the pain management business was certainly a big part of our company, it is important to note that Kimberly Clark did not purchase our three other businesses.

These other businesses consist of interventional cardiology, interventional radiology, and Canadian distribution. Baylis Medical will continue run and grow these businesses, each of which have excellent growth opportunities in front of them. Specifically in our interventional radiology business, we anticipate launching within the next 6 months a full suite of interventional radiology products geared at treating chronic total occlusions. In our cardiology business, we plan on releasing a series of transseptal catheters to complement our ground breaking NRG™ RF Transseptal Needle. Finally, in our Canadian distribution business, we have a recently signed on to represent Cyberonics implantable epilepsy stimulator in Canada that will have an immediate positive impact on our sales.

At Baylis Medical we are very proud of our long standing association with Kimberly Clark. During the next 12 to 18 months we will be working very closely with Kimberly Clark to transition the pain management business over to them. However as you can see, we will also be very busy with the new, excellent opportunities we have coming in our three other businesses.

 

For more information:

Luc Desaulniers, Marketing & Communications
(514) 488-9801
ldesaulniers@baylismedical.com

 

Before use, consult product labels and inserts for any indications, contraindications, hazards, warnings, cautions and instructions for use. CAUTION: Federal Law (USA) restricts the use of this device to or by the order of a physician.

New Technique Uses Radiofrequency for Transseptal Puncture

New Technique Uses Radiofrequency for Transseptal Puncture

Date:

FOR IMMEDIATE RELEASE

New Technique Uses Radiofrequency for Transseptal Puncture

Chicago - Illinois (August 15, 2008) – Baylis Medical announced today the successful, first-in-human, use of a novel medical device that utilizes radiofrequency energy to perform the transseptal puncture. This first-in-human use of the radiofrequency NRG™ Transseptal Needle was performed as an adjunct to an atrial fibrillation ablation at the University of Chicago by Dr. Bradley Knight. The patient had been referred to Dr. Knight after failure to complete the transseptal puncture at another hospital using a standard transseptal needle.

The previous procedure had failed due to scar formation on the atrial septum of the heart, which led to the inability to complete the transseptal puncture. The radiofrequency NRG™ Transseptal Needle utilizes a novel radiofrequency energy technology which is especially useful in patients that have scar formation on their septum. Using this device, Dr. Knight was able to pass the needle smoothly into the left atrium and complete the entire ablation procedure. Dr. Knight believes that it could be the new standard of care, as he stated to the University of Chicago Chronicle: “In a few years, hopefully we’ll look back and think how silly it was the way we were poking needles through like that.”   

 
The transseptal puncture, which is a requirement for atrial fibrillation ablation, is a challenging and specialized procedure used to gain access to the left atrium of the heart. If the puncture is unintentionally made in the incorrect location, it may lead to serious adverse events. The standard transseptal needle utilizes a basic design and can require uncontrolled mechanical force to be used. However, with the new NRG™ Transseptal Needle, the transseptal puncture can be accomplished in a controlled manner with increased safety.  

About Baylis Medical

Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology and interventional radiology. The company’s core expertise lies in electrosurgical systems that are used to deliver various therapeutic treatments. The company has offices in Montreal, Toronto, Vancouver, and London, U.K. For more information, please visit www.baylismedical.com.  

Contact

Luc Desaulniers
Communications Associate
Baylis Medical Company
Tel: 514-488-9801
ldesaulniers@baylismedical.com
http://www.baylismedical.com

###

© Copyright Baylis Medical Company Inc., 2008. Baylis Medical Company Inc. reserves the right to change specifications or to incorporate design changes without notice and without incurring any obligation relating to equipment previously manufactured or delivered. NRG™ and the Baylis Medical logo are trademarks or registered trademarks of Baylis Medical Company Inc. in the United States of America and/or other countries.

Before use, consult product labels and inserts for any indications, contraindications, hazards, warnings, cautions and instructions for use.
CAUTION: Federal Law (USA) restricts the use of this device to or by the order of a physician.

Patents Pending and/or issued